Company Overview

RVAC Medicines has established a team of top-tiered talents in fields of mRNA, vaccines, and lipid nanoparticle (LNP) technologies. We are working to establish a pipeline of innovative products to treat infectious and other diseases with unmet needs. Through our efforts, RVAC Medicines will provide additional protections to ASEAN countries against COVID-19 and SARS-CoV2 variants, as well as innovative treatments against other infectious diseases. To enable this mission and achieve our goals, we are establishing cutting-edge GMP manufacturing facilities that will advance our platform technologies through in-house R&D and external partnerships, allowing for manufacture of state-of-the-art mRNA and nucleic acid delivery technologies.

Incubated by CBC Group, RVAC Medicines is headquartered in Singapore with operations in both Boston and Shanghai. CBC Group is a global leader in healthcare investment with greater than $5 billion of assets under management.

Copyright RVAC Medicines All rights reserved 2022

Terms of use